Time to development of ocular syphilis after syphilis infection.

To provide an estimate of the incubation period of ocular syphilis based on serology using both clinical data and stored serum samples, we retrospectively reviewed patients with HIV-1 infection who presented with ocular syphilis between August 1997 and July 2015 in a tertiary hospital in Japan. The incubation period of ocular syphilis was defined as the time from syphilis infection to the development of ocular symptoms due to ocular syphilis. During the study period, 20 patients were diagnosed with ocular syphilis and 8 patients were enrolled in the present study. All patients were Japanese men who have sex with men with a median age of 46 years (IQR 41.5-53.5). The median CD4 count was 668.5/µL (IQR 567.8-734.3) and 5 of the 8 patients had HIV-1 viral load of less than 50 copies/mL. All study patients presented to our clinic because of the development of ocular symptoms, and they did not have any other symptoms compatible with primary, secondary, or tertiary syphilis. The median time between syphilis infection and development of ocular symptoms was 11 months (IQR 4-19, range 2.5-45). Seven out of eight (87.5%) cases developed ocular syphilis within 2 years of syphilis infection. Ocular syphilis should be suspected even in patients with early syphilis who present with ocular symptoms. Moreover, routine serologic screening for syphilis among patients with HIV-1 infection is critical for prevention of irreversible visual loss in ocular syphilis cases.

[Focus on popular science education of glaucoma and reduce glaucomatous low vision and blindness].

The prevention of blindness caused by glaucoma is a difficult task. In order to accomplish the task better, we need the participation of whole society and popularize relevant medical knowledge. Popular science and related knowledge of glaucoma are needed to the people especially for high risk population. If people know glaucoma better and actively join the screening of glaucoma, we can find and diagnose glaucoma earlier, avoid late treatment and reduce the glaucomatous visual function impairment. For patients who had been diagnosed with glaucoma, they should aware and accept new medical concept and technique through systemic popular science education. They should actively participate the whole procedure of the disease management and improve their compliance and confidence. Academic organization of ophthalmology should participate and guide the patient education, improve the individualized comprehensive health care for the diagnosis and treatment and third-order health care system that is suitable for the condition of our country, help improving the prognosis of glaucoma and life quality related to vision for advanced and late glaucoma. (Chin J Ophthalmol, 2017, 53: 81-84).

Visual Impairment and Blindness Avoided with Ranibizumab in Hispanic and Non-Hispanic Whites with Diabetic Macular Edema in the United States.

OBJECTIVE: To estimate visual impairment (VI) and blindness avoided with intravitreal ranibizumab 0.3 mg treatment for central-involved diabetic macular edema (DME) among Hispanic and non-Hispanic white individuals in the United States. DESIGN: Population-based model simulating visual acuity (VA) outcomes over 2 years after diagnosis and treatment of DME. PARTICIPANTS: Visual acuity changes with and without ranibizumab were based on data from the RISE, RIDE, and DRCR Network trials. METHODS: For the better-seeing eye, VA outcomes included VI, defined as worse than 20/40 in the better-seeing eye, and blindness, defined as VA of 20/200 or worse in the better-seeing eye. Incidence of 1 or both eyes with central-involved DME in 2010 were estimated based on the 2010 United States population, prevalence of diabetes mellitus, and 1-year central-involved DME incidence rate. Sixty-one percent of incident individuals had bilateral DME and 39% had unilateral DME, but DME could develop in the fellow eye. MAIN OUTCOMES MEASURES: Cases of VI and blindness avoided with ranibizumab treatment. RESULTS: Among approximately 102 million Hispanic and non-Hispanic white individuals in the United States 45 years of age and older in 2010, an estimated 37 274 had central-involved DME and VI eligible for ranibizumab treatment. Compared with no ranibizumab treatment, the model predicted that ranibizumab 0.3 mg every 4 weeks would reduce the number of individuals with VI from 11 438 (95% simulation interval [SI], 7249-16 077) to 6304 (95% SI, 3921-8981), a 45% (95% SI, 36%-53%) reduction at 2 years. Ranibizumab would reduce the number of incident eyes with VA worse than 20/40 from 16 910 (95% SI, 10 729-23 577) to 9361 (95% SI, 5839-13 245), a 45% (95% SI, 38%-51%) reduction. Ranibizumab was estimated to reduce the number of individuals with legal blindness by 75% (95% SI, 58%-88%) and the number of incident eyes with VA of 20/200 or worse by 76% (95% SI, 63%-87%). CONCLUSIONS: This model suggests that ranibizumab 0.3 mg every 4 weeks substantially reduces prevalence of VI and legal blindness 2 years after initiating treatment among Hispanic and non-Hispanic white individuals in the United States with central-involved DME that has caused vision loss.

Functional low vision in adults from Latin America: findings from population-based surveys in 15 countries.

OBJECTIVE: To review data on functional low vision (FLV) (low vision-visual acuity (VA) < 6/18 (<20/60) to > perception of light (PL+) in the better eye-that is untreatable and uncorrectable) in adults aged 50 years or older from published population-based surveys from 15 countries in Latin America and the Caribbean. METHODS: Data from 15 cross-sectional, population-based surveys on blindness and visual impairment (10 national and five subnational) covering 55 643 people > 50 years old in 15 countries from 2003 to 2013 were reanalyzed to extract statistics on FLV. Eleven of the studies used the rapid assessment of avoidable blindness (RAAB) method and four used the rapid assessment of cataract surgical services (RACSS) method. For the 10 national surveys, age-and sex-specific prevalence of FLV was extrapolated against the corresponding population to estimate the total number of people > 50 years old with FLV. RESULTS: Age- and sex-adjusted prevalence of FLV in people > 50 years old ranged from 0.9% (Guatemala, Mexico, and Uruguay) to 2.2% (Brazil and Cuba) and increased by age. The weighted average prevalence for the 10 national surveys was 1.6%: 1.4% in men and 1.8% in women. For all 10 national studies, a total of 509 164 people > 50 years old were estimated to have FLV. Based on the 910 individuals affected, the main causes of FLV were age-related macular degeneration (weighted average prevalence of 26%), glaucoma (23%), diabetic retinopathy (19%), other posterior segment disease (15%), non-trachomatous corneal opacities (7%), and complications after cataract surgery (4%). CONCLUSIONS: FLV is expected to rise because of 1) the exponential increase of this condition by age, 2) increased life expectancy, and 3) the increase in people > 50 years old. These data can be helpful in planning and developing low vision services for the region; large countries such as Brazil and Mexico would need more studies. Prevention is a major strategy to reduce FLV, as more than 50% of it is preventable.

Optometric education in Africa: historical perspectives and challenges.

The African continent, with a population of more than one billion and 55 recognized developing countries, is still grappling in some countries with socioeconomic and other challenges inherent in developing countries. The continent is working toward a single political entity known as the African Union, and development is taking place faster than ever in most countries. The continent is known to have high levels of health problems, including visual impairment and blindness. Most nations in the continent are making efforts to reduce the scourge of health problems including visual impairment and blindness. Visual impairment in the continent is mostly caused by refractive errors. Consequently, optometry can help reduce the prevalence of visual impairment on the continent. The educational programs currently offered by the different institutions include Diploma in Optometry (DipOptom), Bachelor of Optometry (BOptom), and Doctor of Optometry (OD). There are 17 established institutions offering optometry degree programs on the continent, of which 14 are fully accredited. Considering the optometric manpower needed in the continent, more optometry institutions need to be established. Staffing and infrastructural and training facilities are major challenges facing the majority of the existing institutions. There is also a need to place greater emphasis on postgraduate education to meet the institutional, national, and international professional training standards and to ensure sustainability of optometry education. This article addresses the historical development, educational issues, challenges, and needs, as well as recommendations, for improving the standard and sustainability of optometric education.

Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration.

Age-related macular degeneration (AMD) is a leading cause of visual dysfunction worldwide. Amyloid ß (Aß) peptides, Aß1-40 (Aß40) and Aß1-42 (Aß42), have been implicated previously in the AMD disease process. Consistent with a pathogenic role for Aß, we show here that a mouse model of AMD that invokes multiple factors that are known to modify AMD risk (aged human apolipoprotein E 4 targeted replacement mice on a high-fat, cholesterol-enriched diet) presents with Aß-containing deposits basal to the retinal pigmented epithelium (RPE), histopathologic changes in the RPE, and a deficit in scotopic electroretinographic response, which is reflective of impaired visual function. Strikingly, these electroretinographic deficits are abrogated in a dose-dependent manner by systemic administration of an antibody targeting the C termini of Aß40 and Aß42. Concomitant reduction in the levels of Aß and activated complement components in sub-RPE deposits and structural preservation of the RPE are associated with anti-Aß40/42 antibody immunotherapy and visual protection. These observations are consistent with the reduction in amyloid plaques and improvement of cognitive function in mouse models of Alzheimer's disease treated with anti-Aß antibodies. They also implicate Aß in the pathogenesis of AMD and identify Aß as a viable therapeutic target for its treatment.

Profile of ocular trauma in the Solomon Islands.

BACKGROUND: The objective of this study was to characterize the causes of ocular trauma and determine the risk factors for infection and vision loss following ocular trauma in the Solomon Islands. DESIGN: A prospective clinic-based study. PARTICIPANTS: A total of 507 patients with ocular trauma who were reviewed at the National Referral Hospital in Honiara or one of five provincial eye clinics were included. METHODS: An interview-based questionnaire to determine the circumstances of ocular trauma, and an ocular examination to elicit the trauma sustained,infectious sequelae and the visual outcome. MAIN OUTCOME MEASURE: Visual acuity. RESULTS: Males were significantly more likely to have ocular trauma than females (P = 0.01). The major cause of ocular trauma in young boys and girls was being poked by a stick, followed by lime burns in young boys. For both genders, physical violence resulted in most injuries across all adult age groups. Microbial keratitis complicated 4.4% of ocular trauma. Monocular vision impairment (<6/18) occurred in 5.5% of participants and was more likely to occur if female (P = 0.02). CONCLUSIONS: Ocular trauma is a significant cause of visual morbidity in the Solomon Islands. The results from this prospective study provide a basis for planning blindness prevention programmes in the Western Pacific.

Is binocular vision worth considering in people with low vision?

In someone with good vision, binocular vision provides benefits which could not be obtained by monocular viewing only. People with visual impairment often have abnormal binocularity. However, they often use both eyes simultaneously in their everyday activities. Much remains to be known about binocular vision in people with visual impairment. As the binocular status of people with low vision strongly influences their treatment and rehabilitation, it should be evaluated and considered before diagnosis and further recommendations.

Making a difference with Vision 2020: The Right to Sight? Lessons from two states of North Western Nigeria.

UNLABELLED: Settings and Aim: The World Health Organization launched in 1999 an initiative to eliminate the global avoidable blindness and prevent the projected doubling of avoidable visual impairment between 1990 and 2020 (Vision 2020: The Right to Sight). The World Health Assembly (WHA) adopted resolutions WHA 59.25, WHA 56.26 urging member states to adopt the Vision 2020 principles. More than 90 nongovernmental development organizations, agencies, and institutions, together with a number of major corporations, are now working together in this global partnership. Two neighboring states in North Western Nigeria provide eye care services using different approaches; one state uses the principles of Vision 2020, the other uses a different strategy. The aim of the study was to assess awareness and utilization of eye care services in two Nigerian states. DESIGN: A population-based cross-sectional interview of households was conducted in two neighboring states using a structured questionnaire. Data analysis was performed using SPSS version 21 and a P < 0.05 was considered as significant. FINDINGS: Participation rate was 97% in the two states. The population in the Vision 2020-compliant state were significantly more aware about general eye care services (80% vs. 44%, P < 0.0005); had less proportion of households unaware of any eye care service (55% vs. 69%, P < 0.0005); and have a significantly higher felt the need to utilize eye care services (47% vs. 5.9%, P < 0.0005). The service utilization rate was however low in the two states. CONCLUSION: The principles of Vision 2020: The Right to Sight is adaptable to different cultures/societies and has demonstrated a potential to increase awareness and a felt need for eye care in poor resource settings.

Current knowledge and trends in age-related macular degeneration: today's and future treatments.

PURPOSE: To address the most dynamic and current issues concerning today's treatment options and promising research efforts regarding treatment for age-related macular degeneration. This review is aimed to serve as a practical reference for more in-depth reviews on the subject. METHODS: An online review of the database PubMed and Ovid were performed, searching for the key words age-related macular degeneration, AMD, VEGF, treatment, PDT, steroids, bevacizumab, ranibizumab, VEGF-trap, radiation, combined therapy, as well as their compound phrases. The search was limited to articles published since 1985. All returned articles were carefully screened, and their references were manually reviewed for additional relevant data. The web page www.clinicaltrials.gov was also accessed in search of relevant research trials. RESULTS: A total of 363 articles were reviewed, including 64 additional articles extracted from the references. At the end, only 160 references were included in this review. CONCLUSION: Treatment for age-related macular degeneration is a very dynamic research field. While current treatments are mainly aimed at blocking vascular endothelial growth factor, future treatments seek to prevent vision loss because of scarring. Promising efforts have been made to address the dry form of the disease, which has lacked effective treatment.

Perspective on ophthalmic support in countries of the developing world.

There are over 300 million people living in the world today who are visually impaired and a further 45 million who are blind. The large majority (90%) of these people live in developing countries, and up to 75% of blindness are avoidable. With cataracts being the major cause of blindness and visual impairment, many ophthalmic aid programmes are aimed at alleviating the enormous burden caused by this readily treatable disease. Having said that, caution should be exercised that short surgical visits to remote rural areas that are not coordinated with local national eye care managers should be discouraged because they do little for the development of sustainable eye care programmes. With this in view, it has become imperative to design blindness prevention and ophthalmic support programmes that are workable, comprehensive, economical and sustainable.

[Integrated therapy of congenital cataract to prevent blindness and low vision].

Congenital cataract is a major cause of treatable blindness in the pediatric population worldwide. Advances in microsurgical techniques have significantly increased the success rate of surgery. However, visual rehabilitation outcomes are not always satisfactory even after a successful surgery. Due to delayed surgery, irrational aphakic correction, and lack of amblyopic training, a large number of infants in China remain blind or low-visioned after cataract surgery. Appropriate timing of surgical intervention, rational surgical methodology as well as systematic optical correction and amblyopic training are critical for the prevention of blindness and low vision in congenital cataract.

[Prevention of blindness is still an arduous task and embarks on a long road in China].

The outcomes from China Nine-Province Survey shows that the prevention of blindness in China have got some achievements, however, the status of blindness and moderate and severe visual impairment is still serious. The prevalence of blindness and moderate and severe visual impairment in some remote areas is higher than the national average level. The major cause of blindness and visual impairment is cataract,however, retinal diseases are found to be the second major cause, which reflects both characteristics of blindness in the developed and developing countries. The prevalence of blindness and moderate and severe visual impairment are 1.93% and 5.31% respectively, however, the cataract surgery coverage rate is only 35.7%. These figures shows that prevention of blindness is still an arduous task and embark on a long road in China. The priority for prevention of blindness should be cataract-related blindness and visual impairment at present. Meanwhile, we should begin to conduct the prevention of the retinal diseases.

Regular provision of outreach increases acceptance of cataract surgery in South India.

OBJECTIVES: The prevalence of visual loss and blindness from cataract remains high in India. Marginalized communities are frequently reached through outreach clinics. The aim of this study was to explore the hypothesis that regular outreach, held in the same location by the same provider, leads to greater acceptance of cataract surgery than outreach clinics that are irregular in terms of timing and location. METHODS: The study was integrated into outreach clinics run in two districts by Sankara Eye Centre, Coimbatore, Southern India. A semi-structured questionnaire was administered to patients who had attended outreach eye clinics and either accepted or not accepted the offer of cataract surgery. RESULTS: Overall acceptance of surgery was high (91.7%), being higher in the district with regular outreach (94.6%vs. 82.3%, P < 0.001). A total of 398 participants (240, 60% acceptors) were interviewed. Acceptors were more likely to live in smaller households and in supportive families than non-acceptors who lived in larger families which could not provide support and where transport and distance were also barriers (P .001). Attending regular outreach and having had first eye cataract surgery were independent predictors of acceptance in a logistic regression model. CONCLUSION: The findings indicate the importance of providers building trust by organizing regular outreach in the same location. Previous eye surgery was also a strong predictor of accepting cataract surgery. To promote universal access to health care, marginalized rural communities will continue to need outreach for some time to come.

[Results of ranibizumab treatment for choroidal neovascularization secondary to pathological myopia]. / Ergebnisse der Therapie choroidaler Neovaskularisationen bei pathologischer Myopie mit Ranibizumab.

PURPOSE: Choroidal neovascularization (CNV) secondary to pathological myopia (PM) occurs in up to 10 % of PM and the natural course often leads to a considerable deterioration of visual acuity. Treatment options like laser or PDT can stabilize visual acuity. Alternatives like ranibizumab are new treatment options that show very promising results. It was the aim of this analysis to evaluate the development of visual acuity and the number of injections needed in patients with myopia-associated secondary CNVs. METHODS: We retrospectively analysed 10 eyes of 9 patients (7 women, 2 men, mean age: 66 years, SD 8.3; range: 54 - 78 years) treated with ranibizumab because of CNV secondary to PM. All eyes were treatment naïve. Criteria for re-treatment were loss of visual acuity and/ or activity in OCT or fluorescence angiography. RESULTS: During the mean follow-up of 10 months (SD 6.1; range: 6 to 26 months) a mean of 2.5 (SD 1.6, range: 1 to 5) injections of ranibizumab was applied. The spherical equivalent was - 12 D (SD 4.8, range - 7,5 D to - 20.5 D). Previous to the first injection mean visual acuity was logMAR 0,64 (SD 0.20) (ETDRS: 52.8; SD: 11.4) and during the follow-up a mean of 3.4 lines (ETDRS: 16.5 letters) was gained (p = 0.008). After one month visual acuity improved to log MAR 0.47 (SD 0.1, p = 0.0012) (ETDRS: 61.7; SD: 6.5), after 3 months log MAR 0.38 (SD 0.1, p = 0.012) (ETDRS: 65.8; SD: 5.6) and after 6 months up to log MAR 0.35 (SD 0.1, p = 0.008) (ETDRS 67.3; SD 5.6). At the end of the follow-up visual acuity was log MAR 0.30 (SD 0.1) (ETDRS: 69.3; SD: 6.7).No patient experienced a loss of visual acuity. No ocular or systemic side effects were observed. CONCLUSION: According to our results treatment of CNV secondary to PM with ranibizumab leads to a substantial improvement of visual acuity. It seems that successful treatment of CNV secondary to PM needs less anti-VEGF injections than the treatment of neovascularizations due to age-related macular degeneration. Anti-VEGF seems to be a promising alternative to PDT and laser photocoagulation in myopia-related CNV.

The peculiar challenges of blindness prevention in Nigeria: a review article.

AIM: To describe the challenges peculiar to Nigeria in the implementation of vision 2020: the right to sight and to proffer solutions as to the way forward METHOD: A review of the recently completed national blindness survey, current literature, and the advocacy experience of the Ophthalmological Society of Nigeria. FINDINGS: The prevalence of blindness in Nigeria is 0.78%. Over 43% of these are blind from cataracts and a further 9% from uncorrected aphakia or complications of couching. 50% of all cataract interventions are carried out by itinerant couchers. Other major causes of blindness are glaucoma (16%) corneal opacities (12%), trachoma (4%), optic atrophy (3%) onchocerciasis (1%) and macular disease (1%). 70% of these are either preventable or reversible. Nigeria has a relatively favourable ophthalmologist/population ratio of about 2.8 per million, but has a low Cataract surgical rate of 300 per million per year. The reasons for this include a lack of ownership of blindness prevention programs, a lack of political will and parlous state of funding for vision 2020. There is an abdication of responsibility for both training and services on the part of government to the International NonGovernmental organisations. Teaching hospitals no longer generate enough patient surgical load to support training. We estimate it would cost N8.5 billion ($56.8 million) to sustain the WHO recommended Cataract Surgical Rate of 3000 per million per year in Nigeria. CONCLUSIONS: Nigeria is not headed in the direction of meeting Vision 2020 targets. Advocacy involving funding through the MDGs, needs to be intensified.

Implications for postoperative visual loss: steep trendelenburg position and effects on intraocular pressure.

Postoperative visual loss (POVL) is a rare but catastrophic complication after nonocular surgery. Previously POVL has been reported in lengthy, prone, lateral, or cardiopulmonary cases, with extreme blood loss, hemodilution, and hypotension. The author's index case of POVL following a lengthy operation in steep Trendelenburg position (ST) prompted study of the relationship between intraocular pressure (IOP), mean arterial pressure (MAP), and time spent in ST. A 3-year investigation of the relationship between IOP and ST procedures is reported. Ocular perfusion pressure (OPP) was calculated from IOP and MAP in supine position and at 30-minute intervals during ST. At start of surgery, IOP of 37 patients ranged from 9 to 28 mm Hg. At 120 minutes, IOP ranged from 25 to 54 mm Hg. The OPP ranged from 50 to 82 mm Hg at start of surgery and from 21 to 75 mm Hg after 120 minutes. Increased IOP and reductions in OPP in relationship to position change were statistically significant (P < .001), with OPP falling below IOP in 10 cases. Findings suggest a relationship between prolonged ST and reduced OPP, challenging the accepted view that cerebral and ophthalmic circulatory autoregulation prevents elevated compartment pressures and reductions in perfusion.

[To promote "Vision 2020" Initiative under the new situation in China].

At present, the prevention of blindness in China is in the favorable period and got some important progress. Recent five years, Chinese government conducted a series of the program for prevention of blindness, cataract surgical rate is increasing. The reform of the medical system conducted by the government is favorable to the prevention of blindness. There have been better situation and enough technique and personnel to conduct cataract surgery. However, prevention of blindness is still a big challenge to Chinese ophthalmological society. Blindness and visual impairment is still a major public health problem in China. The cataract surgical rate is still quite low. Thus, Chinese ophthalmologists should further promote "Vision 2020" Initiative and prevention of blindness in China. They should further recognize the significance for prevention of blindness, strength the construction of the system for prevention of blindness and eye care, actively prevent and control the eye diseases and conduct the research work in the prevention of blindness.

[Sampling and measurement methods of the protocol design of the China Nine-Province Survey for blindness, visual impairment and cataract surgery].

OBJECTIVE: To design the protocol of the China nine-province survey for blindness, visual impairment and cataract surgery to evaluate the prevalence and main causes of blindness and visual impairment, and the prevalence and outcomes of the cataract surgery. METHODS: The protocol design was began after accepting the task for the national survey for blindness, visual impairment and cataract surgery from the Department of Medicine, Ministry of Health, China, in November, 2005. The protocol in Beijing Shunyi Eye Study in 1996 and Guangdong Doumen County Eye Study in 1997, both supported by World Health Organization, was taken as the basis for the protocol design. The relative experts were invited to discuss and prove the draft protocol. An international advisor committee was established to examine and approve the draft protocol. Finally, the survey protocol was checked and approved by the Department of Medicine, Ministry of Health, China and Prevention Program of Blindness and Deafness, WHO. RESULTS: The survey protocol was designed according to the characteristics and the scale of the survey. The contents of the protocol included determination of target population and survey sites, calculation of the sample size, design of the random sampling, composition and organization of the survey teams, determination of the examinee, the flowchart of the field work, survey items and methods, diagnostic criteria of blindness and moderate and sever visual impairment, the measures of the quality control, the methods of the data management. CONCLUSION: The designed protocol became the standard and practical protocol for the survey to evaluate the prevalence and main causes of blindness and visual impairment, and the prevalence and outcomes of the cataract surgery.

Central serous chorioretinopathy in active endogenous Cushing's syndrome.

Multiple case series have provided evidence for a relatively high incidence of central serous chorioretinopathy (CSC) in patients with active Cushing's syndrome (CS). We describe the ophthalmological status in detail of consecutive patients with active endogenous CS (either de novo or recurrent active endogenous CS) in this prospective cohort study. All patients underwent complete ophthalmological examination, including multimodal imaging, which was performed shortly after establishing the diagnosis of active CS in hypercortisolemic state. Eleven CS patients (4 men, 7 women) with active hypercortisolism were included. Abnormalities reminiscent of (subclinical) CSC were found in 3 patients. Optical coherence tomography (OCT) revealed macular subretinal fluid in 1 patient, who was diagnosed as having active CSC and was successfully treated with half-dose photodynamic therapy. Two other patients showed CSC-like abnormalities: an unilateral pseudovitelliform lesion on OCT and hyperfluorescent changes on fluorescein angiography in one patient, and unilateral leakage on fluorescein angiography in the other patient. Mean subfoveal choroidal thickness on enhanced depth imaging OCT was 270 ± 40 µm (range, 178 - 357 µm). Retinal abnormalities resembling (subclinical) CSC may be more common than previously thought in patients with active CS, and may exist even in patients without visual complaints. Clinicians should have a low threshold for ophthalmological evaluation in case of a CS patient with visual symptoms since there may be therapeutic opportunities to prevent vision loss.